GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » ROA %

Aadi Bioscience (FRA:3350) ROA % : -60.20% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aadi Bioscience's annualized Net Income for the quarter that ended in Mar. 2024 was €-67.30 Mil. Aadi Bioscience's average Total Assets over the quarter that ended in Mar. 2024 was €111.81 Mil. Therefore, Aadi Bioscience's annualized ROA % for the quarter that ended in Mar. 2024 was -60.20%.

The historical rank and industry rank for Aadi Bioscience's ROA % or its related term are showing as below:

FRA:3350' s ROA % Range Over the Past 10 Years
Min: -124.58   Med: -38.46   Max: -18.48
Current: -48.81

During the past 4 years, Aadi Bioscience's highest ROA % was -18.48%. The lowest was -124.58%. And the median was -38.46%.

FRA:3350's ROA % is ranked worse than
60.28% of 1551 companies
in the Biotechnology industry
Industry Median: -35.06 vs FRA:3350: -48.81

Aadi Bioscience ROA % Historical Data

The historical data trend for Aadi Bioscience's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience ROA % Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-18.48 -125.53 -36.42 -40.84

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.13 -44.38 -45.19 -47.31 -60.20

Competitive Comparison of Aadi Bioscience's ROA %

For the Biotechnology subindustry, Aadi Bioscience's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aadi Bioscience's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's ROA % distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's ROA % falls into.



Aadi Bioscience ROA % Calculation

Aadi Bioscience's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-60.307/( (173.92+121.432)/ 2 )
=-60.307/147.676
=-40.84 %

Aadi Bioscience's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-67.304/( (121.432+102.187)/ 2 )
=-67.304/111.8095
=-60.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Aadi Bioscience  (FRA:3350) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-67.304/111.8095
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-67.304 / 19.7)*(19.7 / 111.8095)
=Net Margin %*Asset Turnover
=-341.64 %*0.1762
=-60.20 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Aadi Bioscience ROA % Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience (FRA:3350) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines